Alexandra C.’s Post

Join Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience at the 7th Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche. Brian will be featured as a panelist in the session titled “Digital Biomarkers in Neuroscience Today” where the panel will discuss the status of digital biomarkers in the CNS space, transforming clinically relevant symptoms into digitally measurable biomarkers and the progress towards digital biomarkers being used as primary endpoints in clinical trials. #digitalbiomarkers #CNS #clinicaltrials https://lnkd.in/gSMcnfF6

Join Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience at the 7th Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche. Brian will be featured as a panelist in the session titled “Digital Biomarkers in Neuroscience Today” where the panel will discuss the status of digital biomarkers in the CNS space, transforming clinically relevant symptoms into digitally measurable biomarkers and the progress towards digital biomarkers being used as primary endpoints in clinical trials. #digitalbiomarkers #CNS #clinicaltrials https://lnkd.in/eWGeWyPY

Join Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience at the 7th Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche. Brian will be featured as a panelist in the session titled “Digital Biomarkers in Neuroscience Today” where the panel will discuss the status of digital biomarkers in the CNS space, transforming clinically relevant symptoms into digitally measurable biomarkers and the progress towards digital biomarkers being used as primary endpoints in clinical trials. #digitalbiomarkers #CNS #clinicaltrials https://lnkd.in/erNMsDVi

Review of 38 trials assessing #DMT impact on #QOL in people with #MS: The complexity of QOL measurement makes it challenging to draw clear conclusions from the data. Despite some positive impacts of certain DMTs, the lack of a standardized approach to assess disease-specific QOL in MS highlights the need for better incorporation of QOL measures in future clinical trials. https://lnkd.in/gDgKnidz Perrine Janiaud Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB)

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies - FENS Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease Data demonstrates improvement in cognitive function in GBA1 hashtag #Parkinson’s disease model in addition to reversal of motor function deficits https://lnkd.in/gnzP6jg2

Today is the last day of #SfN2023 and the final call to view the latest data on how our ioCells™ are empowering CNS drug discovery! Learn how our ioDisease Model Cells™ for Huntington's disease and amyotrophic lateral sclerosis (ALS) are being used to model neurodegeneration in vitro, to support CNS drug discovery programs at Charles River Laboratories. Poster 467.12 | Establishing a hPSC-derived Huntington’s disease neuronal model suitable for phenotypic drug screening and to identify small molecule modulators of mutant HTT Session: Huntington’s Disease: Molecular and Cellular Mechanisms Time: 11 am - 12 pm Larissa Butler et al, Charles River Laboratories Poster 533.19 | TDP-43 dysfunction and STMN-2 mis-splicing upon proteasomal inhibition in iPSC derived neuronal ALS model Session: ALS: Patient Research and Human-derived Cellular Models Time: 4 - 5 pm Dario Magnani et al, Charles River Laboratories We are also excited to showcase our newest products in the market ioMotor Neurons™ and ioSensory Neurons™! Join the poster sessions to discover the functional data presented by our scientific experts! Poster 489.02 | Rapid and consistent generation of functional motor neurons from reprogrammed human iPSCs using opti-ox technology Session: Motor Neurons: Development, Identification, Intrinsic Properties and Modulation Time : 9 - 10 am Marcos Herrera Vaquero et al, bit․bio Poster 544.05 | Optimised and scalable reprogramming of human iPSCs to generate nociceptor sensory neurons for the study of pain mechanisms and neuropathies Session: Behavioural and Physiological Pain Models Time: 1 - 2 pm Tony Oosterveen, bit․bio View the full agenda: https://hubs.ly/Q028_5kr0 Come meet our scientists at booth 2001! #research #DrugDiscovery #optiox #ioCells #iPSC #neuroscience #HTS #neuron #array #data #microglia #neurodegeneration #ALS #HuntingtonsDisease

Excited to see how this collaboration yields new biomarkers with the following three distinct but interrelated goals: ✅ Monitor ALS disease progression and treatment efficacy across cohorts from multiple participating institutions ✅ Innovate therapeutic strategies and diagnostic tools by better understanding the metabolic landscape of motor neuron cells in ALS patients ✅ Drive precision medicine advances by subsetting patients based on their unique metabo-phenotype.

Wang Liqun has always been fascinated by neuroscience. Early in her career, she did basic biomedical research to better understand a rare neurodegenerative disease called Alexander Disease. This left her wondering, “What can I do to really help these patients?” After spending time in industry, she joined the Wyss Institute’s #BrainTargetingProgram to develop technologies to better deliver drugs to the brain. Learn more about Liqun and her work in this month’s Humans of the Wyss.  #HOWyss #DrugDelivery #NeurodegenerativeDisease #BrainCancer #BrainResearch https://lnkd.in/gEbv8Qt2

Our newly accepted manuscript entitled "Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence" is now available online at the Neurological science journal. You can read it through this link: https://lnkd.in/dz7iNnTz

Now on-demand: Keenan Walker, PhD, discusses how he integrates proteomic, genetic, brain imaging and cerebrospinal fluid biomarkers from cognitively normal individuals who later develop dementia. He also outlines how he is using this information to discover new blood-based biomarkers and potential drug targets. Watch it here: https://bit.ly/45XMt0Q #proteomics #biomarkers #neuroscience #drugdevelopment #drugdiscovery #alzheimersresearch #alzheimers